1.Vanhaesebroeck B, Perry MWD, Brown JR, André F, Okkenhaug K. PI3K inhibitors are finally coming of age [published correction appears in Nat Rev Drug Discov. 2021 Sep 1;:]. Nat Rev Drug Discov. 2021;20(10):741...
(3)耐受度提高:通过抑制CK1-ε(酪蛋白激酶1ε),防止扰乱调节性T细胞的功能,从而提高药物的耐受性。PI3K inhibitors are finally coming of age。 PI3K药物新策略 PI3K降解剂 蛋白水解靶向嵌合体 (PROTACs)是一种异双功能小分子,由两个通过接头连接的募集配体组成。一个配体与...
PI3K inhibitors are finally coming of age Bart Vanhaesebroeck, Matthew W. D. Perry, Jennifer R. Brown, Fabrice André & Klaus Okkenhaug Nature Reviews Drug Discovery volume 20, pages 741–769 (2021)Cite this article 28k Accesses 246 Citations 146 Altmetric Metrics details An Author Corre...
[19] VANHAESEBROECK B, PERRY M W D, BROWN J R, et al. PI3K inhibitors are finally coming of age[J/OL]. Nature Reviews. Drug Discovery, 2021, 20(10): 741-769. DOI:10.1038/s41573-021-00209-1. [20] VANHAESEBROECK B, BURKE J E, MADSEN R R. Precision Targeting of Mutant PI3K...
1.Vanhaesebroeck B, Perry MWD, Brown JR, André F, Okkenhaug K. PI3K inhibitors are finally coming of age [published correction appears in Nat Rev Drug Discov. 2021 Sep 1;:]. Nat Rev Drug Discov. 2021;20(10):741-769. doi:10.1038/s41573-021-00209-1. ...
1.Vanhaesebroeck B, Perry MWD, Brown JR, André F, Okkenhaug K. PI3K inhibitors are finally coming of age [published correction appears in Nat Rev Drug Discov. 2021 Sep 1;:]. Nat Rev Drug Discov. 2021;20(10):741-769. doi:10.1038/s41573-021-00209-1. ...
(3)耐受度提高:通过抑制CK1-ε(酪蛋白激酶1ε),防止扰乱调节性T细胞的功能,从而提高药物的耐受性。PI3K inhibitors are finally coming of age。 PI3K药物新策略 PI3K降解剂 蛋白水解靶向嵌合体 (PROTACs)是一种异双功能小分子,由两个通过接头连接的募集配体组成。一个配体与感兴趣的蛋白质 (POI) 特异性结合,另...
1. Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., Andre, F. & Okkenhaug, K. PI3K inhibitors are finally coming of age. Nat. Rev. Drug Discov. 20, 741–769 (2021).2. Fruman, D. A. et al. The PI3K pathway in human disease. Cell 170, 605–635 (2017).想了解...
[9]Vanhaesebroeck, B., Perry, M., Brown, J. R., André, F., & Okkenhaug, K. (2021). PI3K inhibitors are finally coming of age. Nature reviews. Drug discovery, 20(10), 741–769.[10] Mishra, R., Patel, H., Alanazi, S., Kilroy, M. K., & Garrett, J. T. (2021). ...
3. Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F. & Okkenhaug, K. PI3K inhibitors are finally coming of age. Nat. Rev. Drug Discov.20, 741–769 (2021).4. Ali, K. et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance...